Targeting ferroptosis protects against multiorgan dysfunction and death.
Tom Vanden Berghe(VIB-UGent Center for Medical Biotechnology), Koen Augustyns(University of Antwerp), Evelyne Meyer(Ghent University), Emily Van San(University of Antwerp), Wannes Weyts(VIB-UGent Center for Medical Biotechnology), Bartosz Wiernicki(Ghent University), Andreas Linkermann(Albert Einstein College of Medicine), Ria Roelandt(Ghent University), Marcus Conrad(Helmholtz Zentrum München), Ludwig V. Lamberts(University of Antwerp), Mohan Rajapurkar(Muljibhai Patel Urological Hospital), Wulf Tonnus(University Hospital Carl Gustav Carus), Banibrata Mukhopadhyay, Ines Goetschalckx(University of Antwerp), Jelle Huysentruyt(Ghent University), Sze Men Choi(Ghent University), Alexander L.N. van Nuijs(University of Antwerp), Eric A. J. Hoste(University of Pittsburgh), Catalina Dumitrascu(University of Antwerp), An Vermeulen(Ghent University), Peter Vandenabeele(Ghent University), Ruth Seurinck(Ghent University), Irina Ingold(Helmholtz Zentrum München), Yvan Saeys(University College Ghent), Suhas S. Lele(Muljibhai Patel Urological Hospital), Samya Van Coillie(Ghent University)
Cited by 1
Related Papers
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009
|Cell Death and Differentiation|2008|3.3k
FSP1 is a glutathione-independent ferroptosis suppressor
|Nature|2019|3.2k
A comparison of single-cell trajectory inference methods
|Nature Biotechnology|2019|1.7k
Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup
|Nature Reviews Nephrology|2017|1.5k